

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03321695 ML39852

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Participants also will have progressed on an appropriate approved targeted therapy if their tumor has epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene abnormalities treated in common clinical practice settings in Argentina.

Hoffmann-La Roche

Sponsor

Phase

NCT03321695 ML39852

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

All

Healthy Volunteers

No
